NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
11 trialsNCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02087423 2026-04-06
ATLANTIC
AstraZeneca
Phase 2 Completed
NCT06103864 2026-03-31
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca
Phase 3 Recruiting
NCT04900818 2026-03-05
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
Phase 1 Recruiting
NCT03784014 2025-12-11
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Active not recruiting
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT05043090 2025-05-08
SAMETA
AstraZeneca
Phase 3 Active not recruiting